OncView™ Podcast: EGFR Exon 20 Insertion as a Therapeutic Target in NSCLC


In an OncView™ program, Zofia Piotrowska, MD, touched on testing, treatment approaches, and therapeutic options for EGFR exon 20 insertion mutations in non–small cell lung cancer.

As part of its OncView video series, CancerNetwork® spoke with Zofia Piotrowska, MD, an assistant professor of medicine at Harvard Medical School and a medical oncologist at Massachusetts General Hospital, about recent data and review updates in the treatment landscape for patients with metastatic non–small cell lung cancer harboring EGFR exon 20 insertion mutations.

In the video series, Piotrowska discussed the following:

To watch more videos in the CancerNetwork® OncViewseries, visit cancernetwork.com/oncview.

Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

Related Videos
Video 2 - "MARIPOSA-2 Phase 3 Study Design and Treatment Arms"
Video 1 - "Background on Osimertinib Resistance Mechanisms and Unmet Needs Driving Evaluation of Novel Therapies"
A panel of 4 experts on lung cancer
A panel of 4 experts on lung cancer
Estelamari Rodriguez, MD, MPH, an expert on lung cancer
Christine Bestvina, MD, an expert on lung cancer
A panel of 4 experts on lung cancer
A panel of 4 experts on lung cancer
D. Ross Camidge, MD, PhD, spoke about how the approval of alectinib is the beginning of multiple other approvals for patients with ALK-positive NSCLC.
Alexander Spira, MD, PhD, FACP, an expert on lung cancer
Related Content